Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-14.64M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.53 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -62.82% |
| Return on Assets (Trailing 12 Months) | -50.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.69 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.59 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.02 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.37 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 21.74M |
| Free Float | 18.70M |
| Market Capitalization | $124.36M |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | 2.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |